184 related articles for article (PubMed ID: 33398776)
1. Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice.
Yamauchi R; Takedatsu H; Yokoyama K; Yamauchi E; Kawashima M; Nagata T; Uchida Y; Kitaguchi T; Higashi T; Fukuda H; Tsuchiya N; Takata K; Tanaka T; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
Hepatol Int; 2021 Apr; 15(2):392-404. PubMed ID: 33398776
[TBL] [Abstract][Full Text] [Related]
2. Soyasaponin A
Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
[TBL] [Abstract][Full Text] [Related]
3. Elobixibat for the treatment of constipation.
Chedid V; Vijayvargiya P; Camilleri M
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
[TBL] [Abstract][Full Text] [Related]
4. Impact of elobixibat on liver tumors, microbiome, and bile acid levels in a mouse model of nonalcoholic steatohepatitis.
Sugiyama Y; Yamamoto K; Honda T; Kato A; Muto H; Yokoyama S; Ito T; Imai N; Ishizu Y; Nakamura M; Asano T; Enomoto A; Zaitsu K; Ishigami M; Fujishiro M; Kawashima H
Hepatol Int; 2023 Dec; 17(6):1378-1392. PubMed ID: 37666952
[TBL] [Abstract][Full Text] [Related]
5. Dihydromyricetin ameliorated nonalcoholic steatohepatitis in mice by regulating the composition of serous lipids, bile acids and ileal microflora.
Miao X; Luo P; Liu J; Wang J; Chen Y
Lipids Health Dis; 2023 Aug; 22(1):112. PubMed ID: 37533083
[TBL] [Abstract][Full Text] [Related]
6. Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation.
Miner PB
Expert Opin Pharmacother; 2018 Aug; 19(12):1381-1388. PubMed ID: 30129377
[TBL] [Abstract][Full Text] [Related]
7. Indole supplementation ameliorates MCD-induced NASH in mice.
Zhu B; Li H; Lu B; Guo X; Wu C; Wang F; Li Q; Xie L; Glaser S; Francis H; Alpini G; Wu C
J Nutr Biochem; 2022 Sep; 107():109041. PubMed ID: 35568098
[TBL] [Abstract][Full Text] [Related]
8. Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice.
Li C; Yu S; Li X; Cao Y; Li M; Ji G; Zhang L
Front Pharmacol; 2022; 13():833414. PubMed ID: 35721143
[TBL] [Abstract][Full Text] [Related]
9. Gut Microbiota Plays Essential Roles in Soyasaponin's Preventive Bioactivities against Steatohepatitis in the Methionine and Choline Deficient (MCD) Diet-Induced Non-Alcoholic Steatohepatitis (NASH) Mice.
Su C; Wang J; Luo H; Chen J; Lin F; Mo J; Xiong F; Zha L
Mol Nutr Food Res; 2024 Feb; 68(4):e2300561. PubMed ID: 38234006
[TBL] [Abstract][Full Text] [Related]
10. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
[TBL] [Abstract][Full Text] [Related]
11. Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice.
Li Q; Li M; Li F; Zhou W; Dang Y; Zhang L; Ji G
J Ethnopharmacol; 2020 Aug; 258():112896. PubMed ID: 32325178
[TBL] [Abstract][Full Text] [Related]
12. Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice.
Fuchs CD; Krivanec S; Steinacher D; Mlitz V; Wahlström A; Stahlman M; Claudel T; Scharnagl H; Stojakovic T; Marschall HU; Trauner M
Liver Int; 2020 Jun; 40(6):1366-1377. PubMed ID: 32141703
[TBL] [Abstract][Full Text] [Related]
13. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
[TBL] [Abstract][Full Text] [Related]
14. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
[TBL] [Abstract][Full Text] [Related]
15. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
Nakajima A; Seki M; Taniguchi S
J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
Rudling M; Camilleri M; Graffner H; Holst JJ; Rikner L
BMC Cardiovasc Disord; 2015 Jul; 15():75. PubMed ID: 26197999
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
18. Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs.
Taniguchi S; Yano T; Imaizumi M; Manabe N
Neurogastroenterol Motil; 2018 Dec; 30(12):e13448. PubMed ID: 30129138
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
[TBL] [Abstract][Full Text] [Related]
20. Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis.
Lan T; Xu T; Fu Y; Jiang S; Liang X; Yu Z; Pan L; Rong X; Guo J
Front Endocrinol (Lausanne); 2022; 13():864703. PubMed ID: 35784533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
